Liminatus Pharma, Inc. held its 2026 Annual Meeting of Stockholders on August 3, 2026, where shareholders approved the ratification of Withum Smith+Brown PC as independent auditor and elected Nicholas Fernandez and Dr. Ji Yeon Baek to the Board. Crucially, stockholders authorized the Board to implement a reverse stock split at a ratio of up to 1-for-50 shares to satisfy Nasdaq listing requirements. The company operates in the biopharmaceutical industry.

Liminatus Pharma, Inc. entered into a warrant exercise inducement agreement allowing a holder to exercise 10,344,000 existing warrants at a reduced price of $0.18 per share. In exchange, the company will issue up to 20,688,000 new warrants at an exercise price of $0.18 per share, resulting in approximately $1,861,920 in gross proceeds. The company intends to use these proceeds for working capital and general corporate purposes.